Phaseline

Targets › TLR8

TLR8 (Toll-like receptor 8): drug programs, companies and trials

12 programs from 11 companies in 18 trials: 8 Phase 2, 8 Phase 1, 2 Phase 3; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.

Endosomal receptor that plays a key role in innate and adaptive immunity. Controls host immune response against pathogens through recognition of RNA degradation products specific to microorganisms that are initially processed by RNASET2. (UniProt, Q9NR97)

Open in Phaseline: the race on TLR8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Merck KGaAEnpatoran
Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist
TLR8, TLR7Phase 3Systemic Lupus Erythematosus (SLE); Systematic Lupus ErythematosusMay 2029
Eikon TherapeuticsEIK1001
Toll-like receptor 7/8 (TLR 7/8) agonist
TLR7, TLR8Phase 2NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamous or Non Squamous)Dec 2026
M.D. Anderson Cancer CenterSAR445877
TLR7/8 agonist
TLR7, TLR8Phase 2Non-Small Cell Lung Cancer; Phase 1Feb 2028
Merck KGaAEnpatoran (M5049)
Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist
TLR8, TLR7Phase 2Systemic Lupus ErythematosusAug 2028
Beeline MedicinesAfimetoran (BLN-256)
Toll-like receptor 8 inhibitor; Toll-like receptor 7 inhibitor
TLR8, TLR7Phase 2Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus (CLE)Apr 2029
Solstice OncologyPorustobart
Toll-like receptor 8 (TLR8) agonist
TLR8Phase 2Colon CancerSep 2029
National Institute of Allergy and Infectious Diseases (NIAID)3M-052-AF
Toll-like receptor 7/8 agonist
TLR7, TLR8Phase 1Hiv; HIVDec 2026
Bolt BiotherapeuticsBDC-4182
Anti-CLDN18.2 monoclonal antibody conjugated to TLR7/8 dual agonist
CLDN18, TLR7, TLR8Phase 1Gastric Cancer Adenocarcinoma MetastaticMay 2027
Ascendis Pharma Oncology DivisionTransCon TLR7/8 Agonist
TLR7/8 agonist with extended half-life via TransCon technology
TLR7, TLR8Phase 1Advanced Solid TumorAug 2027
HighField BiopharmaceuticalsHF50
Liposome-encapsulated bifunctional therapeutic; HER2-redirected T-cell engager with TLR7/8
ERBB2, TLR7, TLR8Phase 1Advanced Solid TumorsJun 2028
United ImmunityUI-102
TLR7/8 agonist encapsulated in Cholesteryl Pullulan Nanoparticle
TLR7, TLR8Phase 1Advanced CancerMar 2030
InimmuneINI-4001
TLR7/8 agonist
TLR7, TLR8Phase 1Advanced Solid Tumor–

Conditions

Systemic Lupus Erythematosus (2) Advanced Solid Tumor (2) Systemic Lupus Erythematosus (SLE) (1) Systematic Lupus Erythematosus (1) NSCLC (1) Advanced Melanoma (1) Non Small Cell Lung Cancer (Squamous or Non Squamous) (1) Advanced Cancer (1) Cutaneous Lupus Erythematosus (CLE) (1) Hiv (1) HIV (1) Non-Small Cell Lung Cancer (1)

Modalities

small molecule (6), mixed (5), antibody (1)

Companies

Merck KGaA (2) Eikon Therapeutics (1) United Immunity (1) Beeline Medicines (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) M.D. Anderson Cancer Center (1) Solstice Oncology (1) HighField Biopharmaceuticals (1) Ascendis Pharma Oncology Division (1) Bolt Biotherapeutics (1) Inimmune (1)

Related targets

TLR7 (11) ERBB2 (1) CLDN18 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.